Biocon’s growth formula: Generics & biosimilars – The Times of India
BENGALURU: Biocon is betting big on new product launches in its generics and biosimilars portfolios, which are expected to fuel its expansion in the next 2-3 years. The company is leveraging the Viatris acquisition to provide a significant boost towards an integrated biosimilars enterprise model.This integrated approach encompasses complete oversight of value-generation through development and…